Persistent Or Chronic Immune Thrombocytopenia Itp — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for persistent or chronic immune thrombocytopenia itp . 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
6
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Persistent Or Chronic Immune Thrombocytopenia Itp

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Genzyme Corp 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating persistent or chronic immune thrombocytopenia itp . Each bar = one year. Y-axis scaled to peak year (4 patents).

4
33
1
40
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Wayrilz
RILZABRUTINIB
 Genzyme Corp 6 56 — 2033-03-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9994576 Wayrilz method of use 75 2033-09-06
9266895 Wayrilz method of use 75 2033-09-06
8940744 Wayrilz method of use 75 2033-09-06
12178818 Wayrilz method of use 75 2040-10-13
9580427 Wayrilz composition of matter 17 2033-03-01
11708370 Wayrilz composition of matter 17 2041-02-20

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11708370 Wayrilz composition of matter 17 2041-02-20
9580427 Wayrilz composition of matter 17 2033-03-01
12178818 Wayrilz method of use 75 2040-10-13
9994576 Wayrilz method of use 75 2033-09-06
9266895 Wayrilz method of use 75 2033-09-06
8940744 Wayrilz method of use 75 2033-09-06

Related